Long term observational study to check how the patients with Diabetes are managed by doctors and what are the results of different treatments on health effects (on heart, kidney & other organs) on patients over a period

A Prospective observational study of a pan-India cohort of patients with type 2 diabetes mellitus for macrovascular and microvascular complications, glycemic control, and time to treatment adaptation over 3 years. - LANDMARC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

CTRI

Registry ID

CTRI/2017/05/008452

Enrollment

6300

Registered

2017-05-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 Diabetes Mellitus

Ashok Kumar Das, Hemant Thacker, MANOJ S. CHAWLA, AG Unnikrishnan, SUBHASH KUMAR WANGNOO et al. (8 authors)

Diabetes2024-06-14

10.2337/db24-62-pub

1358-P: Diabetes Control and Complications in East India—Three-Year Results of LANDMARC Trial

Nadeem Rais, Subhankar Chowdhury, Sanjay Kalra, SAGARIKA MUKHARJEE, Tirthankar Chaudhury et al. (12 authors)

Diabetes2024-06-14

10.2337/db24-1358-p

1363-P: Diabetes Control and Complications in West India—Three-Year Results of LANDMARC Trial

Shashank Joshi, Bipin Sethi, AG Unnikrishnan, MANOJ S. CHAWLA, SONALI A. PATANGE et al. (12 authors)

Diabetes2024-06-14

10.2337/db24-1363-p

63-PUB: Diabetes Control and Complications in South India—Three-Year Results of LANDMARC Trial

Hemant Thacker, K.M. PRASANNA KUMAR, Ashok Kumar Das, BALAMURUGAN RAMANATHAN, ARTHUR K. ASIRVATHAM et al. (13 authors)

Diabetes2024-06-14

10.2337/db24-63-pub

1359-P: Diabetes Control and Complications in North India—Three-Year Results of LANDMARC Trial

Ambrish Mithal, SUBHASH KUMAR WANGNOO, Abdul Hamid Zargar, Rajeev Chawla, MUKULESH GUPTA et al. (14 authors)

Diabetes2024-06-14

10.2337/db24-1359-p

The <scp>LongitudinAl</scp> Nationwide <scp>stuDy</scp> on Management And Real‐world <scp>outComes</scp> of diabetes in India over 3 years (<scp>LANDMARC</scp> trial)

Ashok Kumar Das, Sanjay Kalra, Shashank Joshi, Ambrish Mithal, K.M. PRASANNA KUMAR et al. (20 authors)

Endocrinology Diabetes & Metabolism2023-07-014 citations

10.1002/edm2.422

1423-P: Glycemic Status at Three-Year Follow-up in LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India

Shashank Joshi, Ashok Kumar Das, K.M. PRASANNA KUMAR, AMBRISH MITHAL, Sanjay Kalra et al. (19 authors)

Diabetes2023-06-20

10.2337/db23-1423-p

1372-P: Micro and Macro Complications Three-Year Follow-up in LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India

Nadeem Rais, Ashok Kumar Das, Shashank Joshi, AMBRISH MITHAL, Sanjay Kalra et al. (19 authors)

Diabetes2023-06-20

10.2337/db23-1372-p

1435-P: Therapeutic Patterns at Three-Year Follow-up in LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India

Hemant Thacker, Ashok Kumar Das, Shashank Joshi, AMBRISH MITHAL, Sanjay Kalra et al. (19 authors)

Diabetes2023-06-20

10.2337/db23-1435-p

1427-P: Glycemic Trend in Metropolitan vs. Nonmetropolitan Cities of India—Three-Year Follow-up Results of LANDMARC

AG Unnikrishnan, Ashok Kumar Das, Shashank Joshi, AMBRISH MITHAL, Sanjay Kalra et al. (19 authors)

Diabetes2023-06-20

10.2337/db23-1427-p

1333-P: Diabetes Complications in Metropolitan vs. Nonmetropolitan Cities of India—Three-Year Follow-up Results of LANDMARC Trial

Sanjay Kalra, Ashok Kumar Das, Shashank Joshi, AMBRISH MITHAL, K.M. PRASANNA KUMAR et al. (19 authors)

Diabetes2023-06-20

10.2337/db23-1333-p

Two‐year trends from the <scp>LANDMARC</scp> study: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcome in patients with type 2 diabetes mellitus

Ashok Kumar Das, Sanjay Kalra, Shashank Joshi, Ambrish Mithal, Prasanna Kumar K. M. et al. (19 authors)

Endocrinology Diabetes & Metabolism2023-02-012 citations

10.1002/edm2.404

1248-P: Glycemic Trend in Metropolitan vs. Nonmetropolitan Cities of India-Two-Year Results of LANDMARC

AG Unnikrishnan, Ashok Kumar Das, Shashank Joshi, AMBRISH MITHAL, Sanjay Kalra et al. (18 authors)

Diabetes2022-05-311 citations

10.2337/db22-1248-p

1160-P: Diabetes Complications in Metropolitan vs. Nonmetropolitan Cities of India—Two-Year Results of LANDMARC

Sanjay Kalra, Ashok Kumar Das, Shashank Joshi, AMBRISH MITHAL, K.M. PRASANNA KUMAR et al. (18 authors)

Diabetes2022-05-311 citations

10.2337/db22-1160-p

1168-P: Complications in the Second Year of LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India

Nadeem Rais, Ashok Kumar Das, Shashank Joshi, AMBRISH MITHAL, Sanjay Kalra et al. (18 authors)

Diabetes2022-05-311 citations

10.2337/db22-1168-p

1219-P: Therapy Trend in the Second Year of LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India

Hemant Thacker, Ashok Kumar Das, Shashank Joshi, AMBRISH MITHAL, Sanjay Kalra et al. (18 authors)

Diabetes2022-05-311 citations

10.2337/db22-1219-p

1244-P: Glycemic Trend in the Second Year of LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India

Shashank Joshi, Ashok Kumar Das, K.M. PRASANNA KUMAR, AMBRISH MITHAL, Sanjay Kalra et al. (18 authors)

Diabetes2022-05-311 citations

10.2337/db22-1244-p

One‐year trends from the LANDMARC trial: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcomes of type 2 diabetes mellitus

Ashok Kumar Das, Sanjay Kalra, Shashank Joshi, Ambrish Mithal, Prasanna Kumar K. M. et al. (21 authors)

Endocrinology Diabetes & Metabolism2021-12-019 citations

10.1002/edm2.316

1087-P: Therapy Trends at One Year in the Longitudinal LANDMARC Study on Real-World Outcomes in Type 2 Diabetes Patients in India

Hemant Thacker, Ashok Kumar Das, Shashank Joshi, Ambrish Mithal, Sanjay Kalra et al. (20 authors)

Diabetes2021-06-01

10.2337/db21-1087-p

1095-P: Glycemic Trend in Metropolitan versus Non-metropolitan Cities of India: One-Year Results of LANDMARC

AG Unnikrishnan, Ashok Kumar Das, Shashank Joshi, Ambrish Mithal, Sanjay Kalra et al. (20 authors)

Diabetes2021-06-01

10.2337/db21-1095-p

1033-P: Complications at One Year in a Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India (LANDMARC)

Nadeem Rais, Ashok Kumar Das, Shashank Joshi, Ambrish Mithal, Sanjay Kalra et al. (20 authors)

Diabetes2021-06-01

10.2337/db21-1033-p

1041-P: Diabetes Complications among Patients from Metropolitan vs. Non-metropolitan Cities in India: One-Year Results of LANDMARC

Sanjay Kalra, Ashok Kumar Das, Shashank Joshi, Ambrish Mithal, K.M. PRASANNA KUMAR et al. (20 authors)

Diabetes2021-06-01

10.2337/db21-1041-p

1065-P: Glycemic Trend at One Year in a Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India (LANDMARC)

Shashank Joshi, Ashok Kumar Das, K.M. PRASANNA KUMAR, AMBRISH MITHAL, Sanjay Kalra et al. (20 authors)

Diabetes2021-06-01

10.2337/db21-1065-p

Baseline characteristics of participants in the LANDMARC trial: A 3‐year, <i>pan</i>‐india, prospective, longitudinal study to assess management and real‐world outcomes of diabetes mellitus

Ashok Kumar Das, Ambrish Mithal, Shashank Joshi, K.M. PRASANNA KUMAR, Sanjay Kalra et al. (21 authors)

Endocrinology Diabetes & Metabolism2021-02-086 citations

10.1002/edm2.231

1588-P: Therapy Trends in Initial 6 Months of the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC)

ROMIK GHOSH, Ashok Kumar Das, Ambrish Mithal, Shashank Joshi, K.M. PRASANNA KUMAR et al. (16 authors)

Diabetes2020-06-015 citations

10.2337/db20-1588-p

1582-P: Glycemic Change from Baseline in the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC)

ROMIK GHOSH, Ashok Kumar Das, Ambrish Mithal, Shashank Joshi, K.M. PRASANNA KUMAR et al. (16 authors)

Diabetes2020-06-01

10.2337/db20-1582-p

2271-PUB: Rate of Diabetes Complications during the Initial 6 Months of the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC)

ROMIK GHOSH, Ashok Kumar Das, Shashank Joshi, Ambrish Mithal, Prasanna Kumar et al. (16 authors)

Diabetes2020-06-01

10.2337/db20-2271-pub

2258-PUB: Impact of Cardiovascular (CV) Risk Factors during the Initial 6 Months of the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC)

ROMIK GHOSH, Ashok Kumar Das, Shashank Joshi, Ambrish Mithal, K.M. PRASANNA KUMAR et al. (16 authors)

Diabetes2020-06-01

10.2337/db20-2258-pub

Rationale, study design and methodology of the LANDMARC trial: a 3-year, pan-India, prospective, longitudinal study to assess management and real-world outcomes of diabetes mellitus.

Das AK, Mithal A, Kumar KMP, Unnikrishnan AG, Kalra S, Thacker H, Sethi B, Ghosh R, Mathew A, Chodankar D, Mohanasundaram S, Menon SK, Trivedi C, Naqvi M, Kanade V, Salvi V, Chatterjee G, Rais N, Wangnoo SK, Chowdhury S, Zargar AH, Joshi S.

2019-12-157 citations

10.1111/dme.14171

1551-P: Baseline Characteristics of Patients in the First Pan-India, Prospective, Longitudinal Study to Assess Management and Outcomes of T2D in Real-World Settings—LANDMARC

ROMIK GHOSH, Ashok Kumar Das, AG Unnikrishnan, Sanjay Kalra, Hemant Thacker et al. (6 authors)

Diabetes2019-06-01

10.2337/db19-1551-p

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female patients with type 2 diabetes 2. Patient age at diagnosis of T2DM should be more than 25 years and less than years 3.At the time of inclusion in the study, the duration of T2DM since diagnosis should be at least 2 years 4.Patients currently on 2 or more anti-diabetic agents (with or without glycemic control) 5.Signed Informed Consent before inclusion in the study

Exclusion criteria

Exclusion criteria: 1. Known type 1 diabetes mellitus and secondary diabetes (Eg. Gestational diabetes, fibrocalculus pancreatic diabetes). 2. Limited life expectancy due to terminal diseases such as (but not limited to) end stage renal disease (ESRD), cirrhosis of liver, congestive heart failure and active malignancy. 3. Patients on investigational drug or who have participated in a clinical trial in the previous 3 months.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with macrovascular disease over 36 months [Cumulative incidence]: cardiovascular (non-fatal myocardial infarction, non-fatal stroke and cardiovascular death) and peripheral vascular disease (will be defined by Edinburgh Claudication Questionnaire).Timepoint: Every Year	—

Secondary

Measure	Time frame
1. Composite renal and retinal microvascular outcome that included the first occurrence of any of the following: Initiation of retinal photocoagulation, vitreous hemorrhage, diabetes-related blindness, or incident or worsening nephropathy.Timepoint: Every Year	—

Countries

India

Contacts

Public ContactMs Vaishali Kanade

Sanofi India Limited

Deepa.Chodankar@sanofi.com91-9096867313

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 1, 2026

Long term observational study to check how the patients with Diabetes are managed by doctors and what are the results of different treatments on health effects (on heart, kidney & other organs) on patients over a period

Conditions

Related papers

Interventions

Sponsors

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Contacts

Outcome results